TrialClinical drug investigation2014

Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Keiichiro Imanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.